glutathione mutations in sclc patients Frontiers Inhibiting the system xC−/glutathione axis
Inhibiting the system xC glutathione axis selectively targets cancers with mutant p53 accumulation Nature Communications Differential KEAP1 NRF2 mediated signaling widens the therapeutic window of redox targeting drugs in SCLC therapy Nature Communications Antibody drug conjugates: A new twist to overcome EGFR TKIs resistance in non small cell lung cancer ScienceDirect Frontiers Broadening horizons: research on ferroptosis in lung cancer and its potential therapeutic targets
Pay in 4 interest-free payments of $6.75 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13



